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Abstract
Background—The skeleton and liver are frequently involved sites of metastasis in patients with
metastatic renal cell carcinoma (RCC).
Objective—The purpose of this study was to analyze outcomes based on the presence of bone
metastases (BM) and/or liver metastases (LM) in patients with RCC treated with targeted therapy.
Design, Setting and Participants—We conducted a review from the International Metastatic
RCC Database Consortium (IMDC) of 2,027 patients with metastatic RCC.
Outcome Measurements and Statistical Analysis—We analyzed the impact of site of
metastasis on overall survival (OS) and time-to-treatment failure (TTF). Statistical analyses were
performed using multivariable Cox regression.
Results and Limitations—Presence of BM was 34% overall and when stratified by IMDC risk
groups was 27%, 33%, and 43% in favorable, intermediate, and poor-risk groups, respectively
(pitalic>0.001). Presence of LM was 19% overall and higher in the poor-risk patients (23%)
compared to the favorable or intermediate-risk groups (17%) (p=0.003). When patients were
classified into four groups based on the presence of BM and/or LM the hazard ratio (HR), adjusted
for IMDC risk factors, was 1.4 (95% Confidence Interval (CI) 1.22–1.62) for BM, 1.42 (95% CI
1.17–1.73) for LM, and 1.82 (95% CI 1.47–2.26) for both BM and LM compared to other
metastatic sites (pbold>0.0001). The prediction model performance for OS was significantly
improved when BM and LM were added to the IMDC prognostic model (likelihood ratio test
p<0.0001). Data in this analysis was collected retrospectively.
Conclusions—The presence of BM and LM in patients treated with targeted agents has a
negative impact on survival. Patients with BM and/or LM may benefit from earlier inclusion on
clinical trials of novel agents or combination-based therapies.
Keywords
Bone metastases; Liver metastases; mTOR inhibitors; Outcome; Renal cell carcinoma; VEGF
therapy
Introduction
The most common site of metastasis in patients with RCC is the lung, affecting 45–50% of
patients with metastatic disease.[1] Other frequent sites of involvement include the skeleton
and liver, with estimates of involvement of 30% and 20%, respectively.[1] BM from RCC
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cause significant morbidity and are associated with high rates of skeletal complications.
Prior to the era of targeted therapy, the rate of skeletal-related events (SREs), defined as
pathologic fracture, bone radiotherapy, bone surgery, spinal cord compression, and in some
series hypercalcemia, was 74% to upwards of 85%.[2]
Recent advances in our understanding of the pathogenesis of RCC have led to a new
treatment paradigm for patients with metastatic RCC. Though studies of patients treated in
the cytokine era suggest that the presence of BM and/or LM is associated with poor
prognosis, the impact of BM and/or LM on outcomes of patients treated with agents
targeting the vascular endothelial growth factor (VEGF) and mammalian target of
rapamycin (mTOR) axis is largely unknown. We used the IMDC to determine whether
baseline BM and/or LM are associated with worse OS and TTF in patients with metastatic
RCC treated with first-line targeted therapy.
Patients and Methods
Study design
The IMDC is a consecutive patient series from institutions in Canada, Denmark, South
Korea and the United States. We used the IMDC to identify 2,370 patients from 20 centers
treated for metastatic RCC. The database was locked for the current analysis on October 10,
2012. Patient inclusion criteria comprised a diagnosis of metastatic RCC of any histological
subtype treated with first-line targeted therapy. Patients who received prior immunotherapy
were included in the analysis. Patients were excluded from the analysis if they had missing
information regarding baseline number of sites of metastasis, BM, LM, or choice of therapy.
For this study, we included 2,027 patients of all ages with metastatic RCC who received
first-line targeted therapy between April 7, 2003 and August 8, 2012.
We retrospectively collected baseline demographic, clinical and laboratory data, including
those previously found to have prognostic value, on all patients using uniform database
templates to ensure consistent data collection.[3] Laboratory values were standardized
against institutional upper limits of normal and lower limits of normal values. We collected
survival data from patient medical records or publically available records. Institutional
review board approval was obtained from each participating center.
Statistical methods
The primary outcome of this study was OS, which was defined as the time from initiation of
first-line targeted therapy to death from any cause or was censored at the date of last follow-
up. The secondary outcome was TTF, which was defined as the time from initiation of first-
line targeted therapy to date of progression, drug discontinuation, death or was censored at
last follow-up. Distributions of OS and TTF were calculated using the Kaplan-Meier
method. Median OS and TTF along with 95% CIs were reported. Associations between OS
and TTF and site of metastasis were assessed using the log-rank test in univariate analysis or
Wald chi-square test from multivariable Cox regression adjusted for IMDC prognostic
factors.[3] For each of these analyses, two models were undertaken. In model 1, BM (yes
versus no) and LM (yes versus no) were evaluated as two individual factors. In model 2,
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patients were classified into four groups based on the combination of BM and LM (presence
of both BM and LM, presence of either BM or LM, or other metastases). The likelihood
ratio test was also conducted to test the improvement in prediction performance that was
gained by addition of BM and LM to the IMDC prognostic model.[4]
Subgroup analyses were performed in those with: 1) single and multiple sites of metastasis,
2) IMDC favorable, intermediate, and poor-risk groups, and 3) different types of targeted
therapy (sunitinib, sorafenib, and other). All statistical computations were performed using
SAS 9.2 (SAS Institute Inc.) and a p-value (two-sided) < 0.05 was considered significant.
Results
Patient and disease characteristics and clinical outcomes
Patient and disease characteristics at initiation of targeted therapy are displayed in Table 1.
Most patients were men greater than 60 years of age with good performance status and
clear-cell histology. In total, 97.6% (n=1,978) received first-line VEGF targeted therapy,
whereas 2.4% (n=49) received first-line mTOR targeted therapy. The majority of patients
had a previous nephrectomy and less than one third of patients received previous
immunotherapy.
Most patients had greater than one site of metastasis. Stratified by the IMDC risk groups,
more patients with poor-risk disease (82%) had greater than one site of metastasis compared
to favorable or intermediate-risk groups (74%) (p=0.001). The presence of BM was 34%
overall and 27%, 33%, and 43% in the favorable, intermediate, and poor-risk groups,
respectively (p<0.001). The presence of LM was 19% overall and higher in poor-risk
patients (23%) compared to favorable or intermediate-risk groups (17%) (p=0.002).
At the time of analysis, 1,722 (85%) of patients had stopped their first-line therapy. Median
OS after initiation of targeted therapy was 20.5 months with 763 (38%) patients remaining
alive at the time of data analysis. The median time on first-line therapy was 6.7 months
(range 0–91). Median follow-up in living patients was 20.9 months.
The impact of bone and liver metastases on clinical outcomes
We evaluated BM and LM as two individual prognostic factors (Table 2, Model 1). Patients
with BM had a significantly shorter median OS (14.9 versus 25.1 months, p<0.0001) and
TTF (5.7 versus 7.6 months, p<0.0001) than those without BM. Similarly, patients with LM
compared to those without LM had a worse median OS (14.3 versus 22.2 months, p<0.001)
and TTF (5.5 versus 7.3 months, p=0.013). The associations remained in the multivariable
analyses. When patients were further classified into four groups based on the combination of
BM and LM (Table 2, Model 2), the HR was 1.40 for BM, 1.42 for LM, and 1.82 for both
BM and LM when compared to other metastatic sites (p<0.0001). A similar trend was
observed for TTF analysis.
The likelihood ratio tests comparing the IMDC prognostic model alone to the alternative
models with the addition of BM and LM were highly significant (p values<0.001),
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suggesting that inclusion of BM and LM to the IMDC model enhances the prediction
performance of the IMDC prognostic model.
Stratified by single or multiple sites of metastasis
Compared to patients with a single site of metastasis, patients with multiple metastatic sites
had shorter OS (18.2 versus 31.4 months, p<0.0001) and TTF (6.2 versus 8.3 months,
p=0.005). We stratified patients by either a single site of metastasis or two or more
metastatic sites to evaluate the significance of BM and LM on OS and TTF (Table 3, Figure
1). In patients with a single site of metastatic disease, those with BM or LM had shorter
median OS but similar TTF compared to other single sites. There was no significant
difference in multivariable analysis adjusted for IMDC risk factors.
For patients with multiple metastatic sites, median OS was 23.5 months in those without BM
and LM, and was worse in patients with the presence of either BM (16.1 months) or LM
(18.2 months). The combination of both BM and LM had the shortest median OS (10.9
months) (p<0.0001). A similar trend was observed for TTF. The association was retained in
multivariable analysis.
Stratified by the IMDC risk groups
When patients were stratified by the IMDC risk groups (Table 4, Figure 2), those with other
sites of metastasis had the best median OS, while patients with both BM and LM had the
shortest OS in the IMDC favorable and intermediate-risk groups (p<0.05). In the poor-risk
group, there was no difference between bone only, liver only, or the combination of both,
but they were all worse than patients with other metastases. A similar trend was observed for
TTF analysis.
Stratified by type of targeted therapy
In this cohort, the majority of patients received first-line treatment with sunitinib (74%). For
OS, results were similar regardless of first-line therapy. The HR among patients receiving
sunitinib, sorafenib and other therapies was 1.40 (95% CI 1.21–1.62), 1.56 (95% CI 1.16–
2.11) and 1.50 (95% CI 0.91–2.47), respectively, for the presence of either BM or LM, and
was 1.87 (95% CI 1.45–2.43), 2.14 (95% CI 1.29–3.55) and 1.63 (95% CI 0.87–3.08),
respectively, for the presence of both BM and LM compared to patients with other sites of
metastases. For TTF, presence of both BM and LM had a poorer TTF in all treatment groups
compared to other sites of metastasis. There was no difference between presence of BM or
LM compared to other metastases in patients who received sorafenib or other therapies (data
not shown).
The impact of other metastatic sites on clinical outcomes
Table 3 describes the OS and TTF estimates for patients with lung, lymph node, or brain
metastases without BM and LM. In patients with a single metastatic site, lung, lymph node,
brain, or other metastasis sites had improved OS compared to either BM or LM. In patients
with two or more metastatic sites, patients with lung, lymph node, brain, or other metastasis
sites without BM or LM, has improved OS compared those with either BM, LM or both.
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Discussion
In our study, the presence of BM and LM was associated with a clinically significant
negative impact on survival. Our series is currently the largest to date, with over 2,000
patients, evaluating the effect of not only BM but also LM on outcomes of patients with
RCC. Additionally, in our series, we included RCC patients of all histological subtypes. As
the treatment paradigm for patients with metastatic RCC is rapidly evolving, prognostic
factors need to reflect changes in systemic therapy. Our series includes patients treated in the
current era of targeted therapy, receiving a broad range of first-line agents (eight in total),
differentiating it from other analyses evaluating the impact of BM and LM in patients with
RCC.
Many prognostic factors have been investigated in RCC and multiple prognostic models
have been developed. The presence of BM and/or LM has been evaluated and shown to be
prognostic in some models, but not others given the correlation with factors associated with
increased disease burden.[5–8] In our analysis, the significance of the likelihood ratio tests
demonstrates that the addition of site of metastasis to the current IMDC prognostic model
improves the predictive ability of the model.
In addition to providing prognostic information, data regarding site of metastasis may have
therapeutic implications. Additionally, site of metastasis may inform the use of newer agents
currently under investigation in RCC which may have preferential activity in bone, such as
cabozantinib, and osteoclast-targeted agents. Other novel agents currently in preclinical
development, including polymer-targeted angiogenesis inhibitors, which target
angiogenesis-dependent BM, are of particular interest in patients with BM from RCC.[9]
In regards to BM, our findings are consistent with growing evidence that the presence of
BM in metastatic RCC is associated with an adverse effect on outcome (Table 5). In a
retrospective study of 223 patients with clear-cell metastatic RCC treated with first-line
sunitinib, BM was associated with a shorter progression-free survival (PFS) (8.2 versus 19.1
months, p<0.0001) and OS (19.5 versus 38.5 months, p<0.0001).[10] In multivariable
analysis, BM was the independent variable most significantly associated with poor PFS and
OS. There are limited data regarding the impact of BM in patients treated with mTOR
targeted therapy. In a phase III study of 416 patients with metastatic clear-cell RCC treated
with everolimus after progression on VEGF-targeted therapy, presence of BM was an
independent risk factor for shorter PFS and OS.[11] In our study, in multivariable analyses
adjusting for IMDC risk factors, the presence of BM independently predicted worse survival
for the overall cohort and when stratified by IMDC risk groups.
The reason for worse clinical outcomes associated with BM has yet to be elucidated. A
possible explanation includes interactions between tumor cells and the bone
microenvironment which results in a vicious cycle of bone destruction and tumor growth.[12]
Another possible explanation for worse clinical outcomes associated with BM may include
the limited distribution of targeted agents to bone. Given that BM warrant special
consideration for measurability, bone response to targeted agents has not been evaluated in
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patients on clinical trials. Additionally, patients with bone-only metastases are often
excluded from clinical trials given lack of measurable disease by response criteria.
Given the relationship between BM and the bone microenvironment, it is logical to
investigate the use of osteoclast-targeted therapy in metastatic RCC. Currently approved
agents for the prevention of SREs in these patients include zoledronic acid, a potent
bisphosphonate, and denosumab, a monoclonal antibody against the receptor activator of
nuclear factor-κβ ligand, a cytokine important in osteoclast differentiation, activation, and
survival.[13] Retrospective data suggest that bisphosphonate therapy combined with VEGF-
targeted therapy may improve survival in patients with metastatic RCC, however may be
associated with an increased risk of osteonecrosis of the jaw.[14, 15] Additionally, treatment
with zoledronic acid was found to potentiate the effects of mTOR inhibition in preclinical
studies.[16]
In our series, the presence of LM was also associated with a negative impact on outcomes.
Limited studies have suggested worse outcomes in patients with metastatic RCC with LM.
In a retrospective review of patients with metastatic RCC treated with first-line sunitinib,
presence of LM was associated with a shorter PFS (11.3 versus 16.1 months, p=0.3) and OS
(23.6 versus 30.7 months, p=0.3), which was not statistically significant.[10] In a study of
patients with metastatic clear-cell RCC treated with everolimus after progressing on VEFG-
targeted therapy, the presence of LM was an independent risk factor for shorter PFS and OS
(HR 1.42, p=0.016 and HR 1.64, p<0.001, respectively).[11]
The rational for worse outcomes in patients with LM is uncertain. Most targeted agents are
metabolized in the liver and it is possible that patients with LM have some degree of liver
dysfunction. Therapy with targeted agents in this setting could lead to dose reductions and
delays, thus compromising efficacy. Additionally, given significant intratumor heterogeneity
in patients with metastatic RCC, the unique organ microenvironment of the liver may be
selective for a more aggressive clinical phenotype.[17, 18] Molecular characterization of both
BM and LM in patients with RCC may help inform the development of improved prognostic
and predictive biomarkers.
There are several limitations to our study. Data was collected retrospectively. Although the
included patients are consecutive patients, there is the probability of a selection bias. Our
data did not capture information regarding tumor volume, though we did perform a subset
analysis based on single or multiple sites of disease. Additionally, we did not focus on
second-line therapies and use of osteoclast-targeted therapies. Given that we did not have
information regarding the reason for treatment discontinuation, we were unable to calculate
PFS estimates.
Conclusions
In conclusion, the presence of BM and LM in patients with metastatic RCC treated with
targeted therapy has a negative impact on survival. Site of metastasis may possibly be used
for risk-stratification of patients with metastatic RCC. In addition to providing prognostic
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information, data regarding site of metastasis may have therapeutic implications in guiding
clinical decision making.
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Figure 1.
Kaplan-Meier plots of OS by site of metastasis in patients with a single metastatic site (A)
and in patients with > 1 metastatic sites (B). Kaplan-Meier plots of TTF by site of metastasis
in patients with a single metastatic site (C) and in patients with > 1 metastatic sites (D).
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Figure 2.
Kaplan-Meier plots of OS by site of metastasis in patients with IMDC favorable,
intermediate, and poor risk group, respectively.
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Table 1
Patient and disease characteristics at initiation of targeted therapy (n=2,027).
Characteristic n (%)
Age at initiation of therapy
 < 60 years 945 (47%)
  ≥60 years 1,082 (53%)
Karnofsky performance score
  ≥ 80% 1,465 (72%)
 < 80% 445 (22%)
 Unknown 117 (6%)
Sex
 Male 1,494 (74%)
 Female 524 (26%)
 Unknown 9 (<1%)
Pathology
 Clear cell 1,661 (82%)
 Non-clear cell 238 (12%)
 Unknown 128 (6%)
Sarcomatoid features
 Yes 185 (9%)
 No 1,599 (79%)
 Unknown 243 (12%)
Previous nephrectomy
 Yes 1,570 (78%)
 No 455 (22%)
 Unknown 2 (<1%)
Previous immunotherapy
 Yes 444 (22%)
 No 1,583 (78%)
Type of targeted agent
 Sunitinib 1491 (74%)
 Sorafenib 357 (18%)
 Bevacizumab 80 (4%)
 Pazopanib 40 (2%)
 Tivazonib 7 (<1%)
 Axitinib 3 (<1%)
 Temsirolimus 42 (2%)
 Everolimus 7 (<1%)
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Characteristic n (%)
Number of metastases > 1 1,529 (75%)
Metastasis site
 Lung 1,390 (69%)
 Lymph node 864 (43%)
 Bone 693 (34%)
 Liver 381 (19%)
 Brain 165 (8%)
 Other 713 (35%)
IMDC risk group
 Favorable 321 (16%)
 Intermediate 969 (48%)
 Poor 504 (25%)
 Unknown 233 (11%)
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